Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease
Clinical and Molecular Hepatology · 2026
DOI: 10.3350/cmh.2025.1227 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Chieh Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Fatty Liver, Hepatitis C, Hepatitis B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Taiwan University Hospital, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Hepatitis B virus (HBV) remains a major cause of chronic liver diseases, especially in the Asia-Pacific region. In recent decades, coinfection with hepatitis C virus (HCV) and coexistence with metabolic dysfunction-associated steatotic liver disease (MASLD) have emerged as significant clinical concerns among HBV-infected patients. Although global HBV vaccination programs and curative therapies for HCV have led to a marked decline in HBV/HCV coinfection, MASLD is rapidly becoming the predominant comorbidity due to the global surge in metabolic risk factors. HBV/HCV coinfection typically results in more severe liver damage, with unique challenges in antiviral treatment and risk of HBV reactivation post-HCV clearance. In contrast, HBV/MASLD overlap demonstrates complex metabolic-viral interactions that may influence viral replication, hepatitis B surface antigen seroclearance, fibrosis progression, and risk of hepatocellular carcinoma. This review critically compares the epidemiology, clinical outcomes, and management strategies of HBV patients with concurrent HCV or MASLD, while addressing current research gaps and proposing directions for future investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Physical Therapy and Assistive Technology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Hepatitis Research Center, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
Förderung
- National Taiwan University Hospital
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Liu, C., Shih, Y. F., & Liu, C. J. (2026). Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.1227
Vancouver
Liu C, Shih YF, Liu CJ. Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2025.1227
BibTeX
@article{Liu2026,
author = {Liu, Chieh and Shih, Yi-Fen and Liu, Chun-Jen},
title = {Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2025.1227}
}
EUVIMED